News | February 03, 2024
GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
At least one recognised startup in every State and UT; spread across over 80% of districts
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Subscribe To Our Newsletter & Stay Updated
